Qiagen NV reported earnings per share (EPS) of 16 cents in the fourth quarter of 2012, significantly up from the break-even EPS in the year-ago period. After adjusting for certain one-time items (other than stock-based compensation), adjusted EPS were 32 cents in the quarter, beating the Zacks Consensus Estimate by 2 cents and up 3 cents from the prior-year quarter. For fiscal 2012, the adjusted EPS came in at $1.00, in line with the Zacks Consensus Estimate and up 8.7% from fiscal 2011. T
Net sales in the quarter stood at $346.5 million, up 4% year over year (same at constant exchange rates or CER). Additionally, it surpassed the Zacks Consensus Estimate by $17.5 million. AmniSure (acquired in May 2012) made a 2% contribution to growth at CER. Also, excluding the impact of the year-ago product tender, organic growth was 4% at CER. The year-over-year improvement in sales was primarily on the back of strong performances by the company’s molecular diagnostics and applied testing customer classes.